Young-onset colorectal cancer is rising, and CRC demands focus. @MDAndersonnews has created a dedicated Department of Colorectal Medical Oncology to meet that challenge. Honored to serve as its inaugural Chair and partner with new GI Med Onc chair Arvind Dasari @adasarimd #CRCSM
27
35
209
8,193
Delighted to share the full #FDA approval for first-line #CRC encorafenib + cetuximab w/ either FOLFOX or FOLFIRI.
The impact from BREAKWATER: Median OS doubled: 30.3 vs 15.1 months, higher PFS, ORR
Test for BRAF V600E rapidly and treat in first-line!
pfizer.com/news/press-rel…
The impact from BREAKWATER: Median OS doubled: 30.3 vs 15.1 months, higher PFS, ORR
Test for BRAF V600E rapidly and treat in first-line!
pfizer.com/news/press-rel…
12
27
87
5,937
Delighted to be able to share these results. FOLFIRI+EC is an additional treatment option for mCRC patients with BRAF V600E tumors where FOLFOX isn't the right chemo backbone.
🩺 BREAKWATER update: First-line encorafenib/cetuximab + FOLFIRI showed higher response rates than chemo alone (64% vs 40%) in pts with BRAF V600E–mutant mCRC, with similar safety—"supporting a potential new SOC." #colorectalcancer
@skopetz | #ASCOGI26
🔗 ascopost.com/news/january-2…
2
9
39
2,364
Exciting to launch this initiative with the full ADAPT team. How is CRC evolving with treatment and through metastases? We will find out. Read about ASCEND-CRC cell.com/cancer-cell/fu… and the larger ADAPT program cell.com/cancer-cell/fu… in @CancerCell
An example of the type of innovative adaptive design trials being supported by @ARPA_H ADAPT program.
Framework for cancer evolution profiling and interception in colorectal cancer: ASCEND-CRC program
cell.com/cancer-cell/fu…
@skopetz @KimmieNgMD @GIcancerDoc @aparna1024
1
7
26
3,047
Delighted to join Jean-Nicolas Vauthey and Pierre-Alain Clavien to chair the Colorectal Liver Metastasis Consensus Conference. Based on the Danish-Zurich model and led by international experts, this will establish guidelines for the treatment of CRC liver metastases. #crcsm
1
4
23
1,346
Tumor inflammation predicts better response to nivolumab alone in MSI-H CRC, while high mutational burden predicts benefit from nivolumab + ipilimumab. Our Nat Comm paper dives into CM142 and PD1 ± CTLA4 predictors with lead of @michael_overman. rdcu.be/eJHmS #crcsm
7
28
130
16,317
Need a primer about the exciting field of ctDNA defined minimal residual disease and genotyping? I had the pleasure of recording an overview of different uses of ctDNA testing for @Medscape Oncology. #crcmrd
medscape.com/viewarticle/co…
medscape.com/viewarticle/co…
3
5
38
1,710
Shared some insights on #ctDNA’s power to guide clinical decisions in GI cancers—enabling precision treatment, improved surveillance, and earlier intervention for colorectal cancer patients. Excited by the field’s rapid progress towards personalized care!
onclive.com/view/advances-…
onclive.com/view/advances-…
4
5
54
1,686
Exciting science and clinical efficacy in this @MDAndersonnews team science study led by @VanMorrisMD In Cancer Cell.
Triple therapy with IO led to durable responses in BRAF V600E MSS colorectal cancer, showing promise. Randomized study ongoing. #crcsm
cell.com/cancer-cell/fu…
Triple therapy with IO led to durable responses in BRAF V600E MSS colorectal cancer, showing promise. Randomized study ongoing. #crcsm
cell.com/cancer-cell/fu…
6
23
99
6,304
INTERCEPT MRD study: TAS-102 cleared ctDNA in 5/15 (33%) CRC pts with MRD at 6mo, vs 2/30 (7%) in controls, with median DFS to 9.4mo vs 5.8mo. Durable? @skopetz, @kanwal_Raghav, @ryanhuey, @christineparse1, @Moverman322, @PiaMorelli9, @adasarimd. #crcsm @MDAndersonNews
2
3
24
1,430
Targeting the YAP-SDC1 axis overcomes resistance to KRASi in GI cancers by blocking SDC1-driven macropinocytosis and RTK activation, offering a promising strategy for KRASi resistance. @wantong_yao @HaoqiangY @CellRepMed #crcsm To the clinic! pubmed.ncbi.nlm.nih.gov/40713971/
3
13
68
6,398
Important team finding: Fusions occur in 1.3% of mCRC w/ focused partner-agnostic ctDNA assay, but vast majority are subclonal after EGFRi and likely wouldn't provide meaningful benefit if targeted.
Keep hunting for the very rare clonal fusions for clinical benefit!
Keep hunting for the very rare clonal fusions for clinical benefit!
💥New paper out!
We reanalyzed raw sequencing data from 18,558 standard-of-care Guardant360 ctDNA assays in advanced #colorectalcancer using a partner-agnostic fusion caller.
🧬 Fusions in 1.3% of patients
🧪 93% were subclonal — enriched after EGFR therapy
🔗 Clonal fusions linked to MSI-H tumors
💡 Subclonal fusions may signal impending acquired resistance to targeted therapies like EGFR inhibitors — offering a window for earlier intervention.
📄rdcu.be/exqmR
Thanks to Andrew Pellatt for being a great co-fellow and letting me participate in this work along some of the defining leaders in CRC like @VanMorrisMD @skopetz @ryanhuey !
@GuardantHealth @TheGutOncLab @OncoAlert
2
4
33
3,678
Delighted to visit National Cancer Center Hospital East In Tokyo and connect with dear colleagues. Wonderful updates from SCRUM and MONSTAR program, led by @TakayukiYoshin5 and kindly hosted by Dr. Bando. Looking forward to more collaborations on MRD! #crcsm
4
0
13
741
Updated precemtabart tocentecan (M9140, CEACAM ADC) data in mCRC presented at ASCO '25: 31% response rate and mPFS of 6.9m in 100% irinotecan pretreated patients. ADCs can overcome TOP1 relative resistance. ascopubs.org/doi/10.1200/JC… #crcsm
1
4
31
1,546
Precemtabart tocentecan, an anti-CEACAM5 ADC, is active in heavily pretreated metastatic colorectal cancer—median PFS is 6.9 months, and 72% disease control at 12 weeks. First CRC cohort reported in @NatureMedicine. #crcsm
2
14
84
5,610
A nice overview from our talented Dr Fangman and @kanwal_raghav. Worth a read for updates on the rapidly moving field.
Thank you for the opportunity to discuss this important topic in the treatment of patients with #CRC and thankful for the wonderful mentorship of @skopetz and @kanwal_raghav
4
1
23
5,103
A well laid out thread on barriers for PS trainees and the “cliff” after ending formal training, among other barriers. Really highlights the key issues.
1
0
12
2,646
We are delighted to have you join GI Med Onc faculty at @MDAndersonnews and be able to continue the great work you have started with @ParseghianC and others!
🎉 Excited to stay on as Assistant Professor in GI Medical Oncology at @MDAndersonNews after graduation. Immensely grateful to my mentors & the support of my family and friends. Thankful to our patients and looking forward to working together to #EndCancer 🚀 #CRCSM #CCAhope
2
1
35
4,970
RT MDAndersonNews: Our experts will present their latest research at #ASCO23, including studies of acute lymphoblastic leukemia, KRAS G12C…
1
1
28
1,983